Full Press Release Details
of Annual General Meeting and Extraordinary General Meeting
Cottage, New York, June 11, 2008 -
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced a notice
convening its Annual General Meeting ("AGM") and Extraordinary General Meeting
("EGM"). The AGM and EGM will take place at the Conference Room at the Company's
Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel
76100, at 4:00 p.m. Israel time, and 4:30 p.m. Israel time, respectively,
AGM it is proposed that:
EGM it is proposed that:
Notice of the AGM and EGM is available for the public at the US Securities
Exchange Edgar site: http://www.sec.gov/
the Israel Securities Authority's site: www.magna.isa.gov.il.
XTL BIOPHARMACEUTICALS LTD.
Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics
for the treatment of diabetic neuropathic pain and HCV. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL
out-licensed its novel pre-clinical HCV small molecule inhibitor program.
also has an active in-licensing and acquisition program designed to identify
acquire additional drug candidates. XTL is publicly traded on the NASDAQ
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).
Bentsur, Chief Executive Officer
+1-(845)-267-0707 ext. 225